astrazeneca oral glp 1 launches GLP-1 combo to treat obesity co-morbidities AstraZeneca unveils data behind Phase

Not unprecedented in principlebut unusual in speed and concentration

Purity is reported by HPLC at roughly 99%, and the Certificate of Analysis (COA) for the batch is published rather than described Peptide Partners COAs are independently verified through Finnrick, and a Janoshik COA is available for review

Environmental toxins and Parkinsons disease

Beogo R, Nikiema Z, Traore SS, Bouletreau P

It also requires reform of systems that enable pharmaceutical companies to wield patent monopolies for longer than intended in order to maximize profits at the expense of public health

how many people who qualify to take the drug use it